Cargando…

Limited Durability of Viral Control following Treated Acute HIV Infection

BACKGROUND: Early treatment of acute HIV infection with highly active antiretroviral therapy, followed by supervised treatment interruption (STI), has been associated with at least transient control of viremia. However, the durability of such control remains unclear. Here we present longitudinal fol...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufmann, Daniel E, Lichterfeld, Mathias, Altfeld, Marcus, Addo, Marylyn M, Johnston, Mary N, Lee, Paul K, Wagner, Bradford S, Kalife, Elizabeth T, Strick, Daryld, Rosenberg, Eric S, Walker, Bruce D
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC524377/
https://www.ncbi.nlm.nih.gov/pubmed/15526059
http://dx.doi.org/10.1371/journal.pmed.0010036
_version_ 1782121899453579264
author Kaufmann, Daniel E
Lichterfeld, Mathias
Altfeld, Marcus
Addo, Marylyn M
Johnston, Mary N
Lee, Paul K
Wagner, Bradford S
Kalife, Elizabeth T
Strick, Daryld
Rosenberg, Eric S
Walker, Bruce D
author_facet Kaufmann, Daniel E
Lichterfeld, Mathias
Altfeld, Marcus
Addo, Marylyn M
Johnston, Mary N
Lee, Paul K
Wagner, Bradford S
Kalife, Elizabeth T
Strick, Daryld
Rosenberg, Eric S
Walker, Bruce D
author_sort Kaufmann, Daniel E
collection PubMed
description BACKGROUND: Early treatment of acute HIV infection with highly active antiretroviral therapy, followed by supervised treatment interruption (STI), has been associated with at least transient control of viremia. However, the durability of such control remains unclear. Here we present longitudinal follow-up of a single-arm, open-label study assessing the impact of STI in the setting of acute HIV-1 infection. METHODS AND FINDINGS: Fourteen patients were treated during acute HIV-1 infection and subsequently subjected to an STI protocol that required retreatment if viral load exceeded 50,000 RNA copies/ml plasma or remained above 5,000 copies/ml for more than three consecutive weeks. Eleven of 14 (79%) patients were able to achieve viral loads of less than 5,000 RNA copies/ml for at least 90 d following one, two, or three interruptions of treatment. However, a gradual increase in viremia and decline in CD4+ T cell counts was observed in most individuals. By an intention-to-treat analysis, eight (57%), six (43%), and three (21%) of 14 patients achieved a maximal period of control of 180, 360, and 720 d, respectively, despite augmentation of HIV-specific CD4+ and CD8+ T cell responses. The magnitude of HIV-1-specific cellular immune responses before treatment interruption did not predict duration of viremia control. The small sample size and lack of concurrent untreated controls preclude assessment of possible clinical benefit despite failure to control viremia by study criteria. CONCLUSIONS: These data indicate that despite initial control of viremia, durable viral control to less than 5,000 RNA copies/ml plasma in patients following treated acute HIV-1 infection occurs infrequently. Determination of whether early treatment leads to overall clinical benefit will require a larger and randomized clinical trial. These data may be relevant to current efforts to develop an HIV-1 vaccine designed to retard disease progression rather than prevent infection since they indicate that durable maintenance of low-level viremia may be difficult to achieve.
format Text
id pubmed-524377
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-5243772004-11-02 Limited Durability of Viral Control following Treated Acute HIV Infection Kaufmann, Daniel E Lichterfeld, Mathias Altfeld, Marcus Addo, Marylyn M Johnston, Mary N Lee, Paul K Wagner, Bradford S Kalife, Elizabeth T Strick, Daryld Rosenberg, Eric S Walker, Bruce D PLoS Med Research Article BACKGROUND: Early treatment of acute HIV infection with highly active antiretroviral therapy, followed by supervised treatment interruption (STI), has been associated with at least transient control of viremia. However, the durability of such control remains unclear. Here we present longitudinal follow-up of a single-arm, open-label study assessing the impact of STI in the setting of acute HIV-1 infection. METHODS AND FINDINGS: Fourteen patients were treated during acute HIV-1 infection and subsequently subjected to an STI protocol that required retreatment if viral load exceeded 50,000 RNA copies/ml plasma or remained above 5,000 copies/ml for more than three consecutive weeks. Eleven of 14 (79%) patients were able to achieve viral loads of less than 5,000 RNA copies/ml for at least 90 d following one, two, or three interruptions of treatment. However, a gradual increase in viremia and decline in CD4+ T cell counts was observed in most individuals. By an intention-to-treat analysis, eight (57%), six (43%), and three (21%) of 14 patients achieved a maximal period of control of 180, 360, and 720 d, respectively, despite augmentation of HIV-specific CD4+ and CD8+ T cell responses. The magnitude of HIV-1-specific cellular immune responses before treatment interruption did not predict duration of viremia control. The small sample size and lack of concurrent untreated controls preclude assessment of possible clinical benefit despite failure to control viremia by study criteria. CONCLUSIONS: These data indicate that despite initial control of viremia, durable viral control to less than 5,000 RNA copies/ml plasma in patients following treated acute HIV-1 infection occurs infrequently. Determination of whether early treatment leads to overall clinical benefit will require a larger and randomized clinical trial. These data may be relevant to current efforts to develop an HIV-1 vaccine designed to retard disease progression rather than prevent infection since they indicate that durable maintenance of low-level viremia may be difficult to achieve. Public Library of Science 2004-11 2004-10-26 /pmc/articles/PMC524377/ /pubmed/15526059 http://dx.doi.org/10.1371/journal.pmed.0010036 Text en Copyright: © 2004 Kaufmann et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Kaufmann, Daniel E
Lichterfeld, Mathias
Altfeld, Marcus
Addo, Marylyn M
Johnston, Mary N
Lee, Paul K
Wagner, Bradford S
Kalife, Elizabeth T
Strick, Daryld
Rosenberg, Eric S
Walker, Bruce D
Limited Durability of Viral Control following Treated Acute HIV Infection
title Limited Durability of Viral Control following Treated Acute HIV Infection
title_full Limited Durability of Viral Control following Treated Acute HIV Infection
title_fullStr Limited Durability of Viral Control following Treated Acute HIV Infection
title_full_unstemmed Limited Durability of Viral Control following Treated Acute HIV Infection
title_short Limited Durability of Viral Control following Treated Acute HIV Infection
title_sort limited durability of viral control following treated acute hiv infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC524377/
https://www.ncbi.nlm.nih.gov/pubmed/15526059
http://dx.doi.org/10.1371/journal.pmed.0010036
work_keys_str_mv AT kaufmanndaniele limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection
AT lichterfeldmathias limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection
AT altfeldmarcus limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection
AT addomarylynm limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection
AT johnstonmaryn limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection
AT leepaulk limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection
AT wagnerbradfords limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection
AT kalifeelizabetht limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection
AT strickdaryld limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection
AT rosenbergerics limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection
AT walkerbruced limiteddurabilityofviralcontrolfollowingtreatedacutehivinfection